Large cell carcinoma of the lung natural history

Jump to navigation Jump to search

Large Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Large Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Large cell carcinoma of the lung natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Large cell carcinoma of the lung natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Large cell carcinoma of the lung natural history

CDC on Large cell carcinoma of the lung natural history

Large cell carcinoma of the lung natural history in the news

Blogs on Large cell carcinoma of the lung natural history

Directions to Hospitals Treating Large cell carcinoma of the lung

Risk calculators and risk factors for Large cell carcinoma of the lung natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes. Large cell carcinoma of the lung is a locally aggressive tumor. Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years. Common sites of metastasis include adrenal gland, bone, brain, and liver. Complications of large cell carcinoma of the lung, include: acute respiratory failure, malignant pleural effusion, metastases, and pneumonia. Features associated with worse prognosis are presence of lymphatic invasion, location of lesion, gene expression profile, performance status, presence of satellite lesions, and presence of regional or distant metastases. Prognosis is generally regarded as poor.

Natural History

  • If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes.[1]
  • Large cell carcinoma of the lung is a locally aggressive tumor.
  • Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer.
  • Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years.[1]
  • Common sites of metastasis include adrenal gland, bone, brain, and liver

Complications

  • Complications of large cell carcinoma of the lung, include:

Prognosis

  • Prognosis of large cell carcinoma of the lung is generally regarded as poor
  • Features associated with worse prognosis in large cell carcinoma of the lung include:[2]
  • Histologic subtype of large cell neuroendocrine tumor
  • Presence of lymphatic invasion
  • Location of lesion
  • Poor performance status
  • Presence of satellite lesions
  • Presence of regional or distant metastases
  • 5 year median survival rate depends on stage of resection:[3][4]
    • Resectable stage 1- 33%
    • Resectable stage 2- 23%
    • Resectable stage 3- 8%
    • Resectable stage 4- 9.2-12.6 (months)

References

  1. 1.0 1.1 Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E (2007). "Prognosis of lung cancer patients with life-threatening complications". Chest. 131 (3): 840–6. doi:10.1378/chest.06-2244. PMID 17356101.
  2. Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, DeCamp MM (2011). "Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?". J Thorac Oncol. 6 (6): 1050–8. doi:10.1097/JTO.0b013e318217b6f8. PMID 21566535.
  3. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K (January 2006). "Neuroendocrine neoplasms of the lung: a prognostic spectrum". J. Clin. Oncol. 24 (1): 70–6. doi:10.1200/JCO.2005.04.1202. PMID 16382115.
  4. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (August 1998). "Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid". Am. J. Surg. Pathol. 22 (8): 934–44. PMID 9706973.


Template:WikiDoc Sources